Benitec Biopharma Inc. (BNTC): Total Liabilities
$5.61M
As of 2026-06-30
+9.6%
3-year compound annual growth
+32.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $5.61M | +144.2% | 2026-09-14, Balance as of period end |
| 2025-06-30 | $2.30M | -53.7% | 2026-09-14, Balance as of period end |
| 2024-06-30 | $4.96M | +16.4% | 2026-03-20, Balance as of period end |
| 2023-06-30 | $4.26M | +37.9% | 2024-09-26, Balance as of period end |
| 2022-06-30 | $3.09M | +125.8% | 2023-09-21, Balance as of period end |
| 2021-06-30 | $1.37M | +1.5% | 2022-09-02, Balance as of period end |
| 2020-06-30 | $1.35M | -48.9% | 2021-09-20, Balance as of period end |
| 2019-06-30 | $2.64M | n/a | 2020-09-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $5.61M | +144.2% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $33.55M | +28.6% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $123.36M | -15.4% |
| PepGen Inc. (PEPG) | 2025-12-31 | $26.46M | -18.0% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $33.15M | -1.4% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $10.20M | -9.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $32.23M | -45.6% |
Compare BNTC, ANRO, LXRX, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗